Avanir files $75 million shelf for stock, debt, preferreds, warrants

By Devika Patel

Knoxville, Tenn., Sept. 8 - Avanir Pharmaceuticals, Inc. filed a $75 million shelf registration in an S-3 filing with the Securities and Exchange Commission.

The registration covers common stock, preferred stock, debt securities and warrants.

Debt securities may be convertible.

Proceeds will be used to fund the further development of Zenvia, for clinical trials and for general and administrative expenses. The company also may use a portion of the proceeds to pay off debt and acquire or invest in complementary businesses, products and technologies.

Based in San Diego, Avanir develops therapeutic treatments for central nervous system disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.